Lung Cancer Incidence and Mortality with Extended Follow-up during Screening.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Long non-coding RNA GNAS-AS1 knockdown inhibits proliferation and epithelial-mesenchymal transition of lung adenocarcinoma cells via the microRNA-433-3p/Rab3A axis.Open medicine (Warsaw, Poland) · 2023
   Article
2. COL8A1 Promotes NSCLC Progression Through IFIT1/IFIT3-Mediated EGFR Activation.Frontiers in oncology · 2022
   Article
3. Effect of ultrasound-guided pulsed radiofrequency on intercostal neuralgia after lung cancer surgery: A retrospective study.Medicine · 2021
   Observational
4. Lung cancer associated with cystic airspaces: Current concept, pathogenesis, imaging features, pathological basis, and management.Science progress
   Review

Corrections and comments

• Comment on
  Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as